Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer

Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer

Immune checkpoint inhibitors (ICIs), including antibodies that target programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA4), represent some of the most important breakthroughs in new drug development for oncology therapy from the past...

Full description

Bibliographic Details
Main Authors: Ching-Hung Hsieh, Cheng-Zhe Jian, Liang-In Lin, Guan-Sian Low, Ping-Yun Ou, Chiun Hsu, Da-Liang Ou
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
immune checkpoint inhibitor
CXCL13/CXCR5
tertiary lymphoid structure
Online Access:https://www.mdpi.com/2072-6694/14/2/294

Internet

https://www.mdpi.com/2072-6694/14/2/294

Similar Items